IP Library Granted Patent US 6,855,336
Granted Patent B2
US 6,855,336 · App. 10/712,505 · Granted Feb 15, 2005

Omeprazole formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,855,336
App. No.
10/712,505
Granted
Feb 15, 2005
Kind
B2
Abstract

A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of: (a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysing and arginine; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent which is applied from an organic solvent based system.

Claims (8)

1. A method for preparing a stable oral pharmaceutical dosage formulation which consists of:

(a) forming a pellet core consists of 10 to 50 weight percent based on the total weight of the core of omeprazole or a pharmaceutically acceptable salt, a surface active agent, a filler, a binder and 0.5 to 10 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine; and

(b) applying an enteric coating directly onto the core without a separating layer wherein the enteric coating layer surrounds the core and consisting essentially of an enteric coating agent, 5 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and optionally a plasticizer.

2. The method recited in claim 1 wherein the enteric coating layer is applied from an organic solvent based system.

3. The method recited in claim 1 wherein the step of forming the core further comprises the step of applying the core ingredients onto an inert core.

4. The method recited in claim 1 wherein the pharmaceutically acceptable alkaline agent is about 1 to about 3% of the total weight of the core.

5. The method recited in claim 1 wherein the inert processing aid is selected from the group consisting of talc, silicon dioxide and magnesium stearate.

6. The method recited in claim 5 wherein the inert processing aid is talc.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2005
From: BANK OF AMERICA, N.A., AS AGENT
To: ANDA, INC.; ANDRX CORPORATION; ANDRX LABS, LLC; ANDRX LABORATORIES, INC.; ANDRX LABS, INC.; ANDRX PHARMACEUTICALS, LLC; CYBEAR, LLC; MEDICONSULT.COM, INC.
Reel/Frame 016674/0980 →
SECOND SUPPLEMENTAL SECURITY AGREEMENT Recorded Jan 25, 2005
From: ANDRX LABS, LLC; ANDA, INC.; ANDRX PHARMACEUTICALS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 016180/0093 →